Holen Sie sich die Stockscreener-App
2.57
3.75%
-0.10
Handel nachbörslich:
2.65
0.08
+3.11%
AIM ImmunoTech Inc Aktie (AIM) Neueste Nachrichten
AIM ImmunoTech to present at Webull Financial Corporate Connect webinar. - AInvest
AIM ImmunoTech CEO to Share Company Updates at Webull's Biotech Investment Series - Stock Titan
AIM ImmunoTech Presents at Webull Financial Corporate Connect Webinar Series: Biotech/MedTech. - AInvest
AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech - Yahoo Finance
AIM ImmunoTech Announces Pricing of $8.0 Million Public Offering - 富途牛牛
AIM ImmunoTech’s Oncology Drug Ampligen to Be Featured in - GlobeNewswire
AIM ImmunoTech's Oncology Drug Ampligen to Be Featured in Key Pr - GuruFocus
Breakthrough: New Cancer Drug Ampligen Delivers Promising Results in Pancreatic, Ovarian, and Breast Cancer Trials - Stock Titan
AIM ImmunoTech’s Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025) - Yahoo Finance
AIM ImmunoTech (AIM) Advances Clinical Trials and Strengthens Financial Position - GuruFocus
AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on - GuruFocus
AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval | AIM Stock News - GuruFocus
AIM ImmunoTech Builds Positive Momentum and Reiterates - GlobeNewswire
Breakthrough in Pancreatic Cancer Treatment: AIM's Ampligen-Imfinzi Combo Shows Positive Survival Data - Stock Titan
AIM ImmunoTech Surges Amid Key Developments, Raises $8 Million in Public Offering - AInvest
AIM ImmunoTech Closes $8 Million Public Offering - The Globe and Mail
Latest News - Asia Food Journal
AIM ImmunoTech Announces Closing of $8.0 Million Public Offering - GlobeNewswire
AIM ImmunoTech's $8.0M Capital Raise: A Strategic Move to Fuel Ampligen's Clinical Progress and Investor Value? - AInvest
AIM ImmunoTech closes public offering, raises $8 mln. - AInvest
AIM ImmunoTech Secures $8M Funding: New Shares at $4.00 Plus 5-Year Warrants - Stock Titan
AIM ImmunoTech reports Ampligen combo trial data for pancreatic cancer - MSN
Biotech Alert: Searches spiking for these stocks today - TipRanks
AIM ImmunoTech's Stock Falls 50% Following $8M Securities Offering - AInvest
Evaluating AIM ImmunoTech's Capital Raise: A Strategic Crossroads for Investors - AInvest
AIM Shares Fall After Pricing of $8 Million Public Offering - MarketScreener
Crude Oil Gains Over 1%; UnitedHealth Earnings Miss Views - Benzinga
AIM ImmunoTech stock plunges after pricing $8 million public offering By Investing.com - Investing.com Australia
AIM ImmunoTech stock plunges after pricing $8 million public offering - Investing.com
US Stocks Mixed; Procter & Gamble Posts Upbeat Earnings - Benzinga
AIM ImmunoTech Stock Dives 50% After Priced Public Offering - AInvest
Why Is AIM ImmunoTech Stock (AIM) Down 50% Today? - TipRanks
AIM ImmunoTech prices $8 million public offering at $4.00 per share - Investing.com
AIM ImmunoTech Plunges 51.11% Amid Market Volatility - AInvest
AIM ImmunoTech prices 2M shares at $4.00 in public offering - TipRanks
AIM ImmunoTech Announces $8 Million Public Offering at $4 per Share with Accompanying Warrants. - AInvest
AIM ImmunoTech Secures Fresh Capital: $8M Offering Includes Dual Warrant Structure at $4.00 - Stock Titan
AIM ImmunoTech Inc Plunges 38.33% Amid Trading Halt - AInvest
AIM ImmunoTech Stock Plunges 40.97% on Volatility - AInvest
Why Celestica Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga
AIM ImmunoTech Plunges 27.08% Amid Volatility Concerns - AInvest
AIM ImmunoTech Reports Positive Mid-year Safety and - GlobeNewswire
AIM ImmunoTech Inc. Trading Resumes: Enhanced Tools and Expert Analysis Available for Investors - AInvest
Crude Oil Gains 2%; CEA Industries Shares Spike Higher - Benzinga
Why Is Micro-Cap AIM ImmunoTech Stock Surging? - Benzinga
AIM ImmunoTech's Ampligen: A Promising Catalyst for Shareholder Value in Pancreatic Cancer Therapy - AInvest
US Stocks Mixed; Enterprise Products Partners Posts Upbeat Earnings - Benzinga
AIM ImmunoTech Reports Positive Phase 2 Study Results - TipRanks
Trading Resumes for AIM ImmunoTech (AIM) Inc - GuruFocus
AIM ImmunoTech (AIM) reveals positive Phase 2 Ampligen pancreatic data | AIM SEC FilingForm 8-K - Stock Titan
AIM ImmunoTech Reports Positive Mid-year Safety and Efficacy Data from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer - GlobeNewswire
Breakthrough in Pancreatic Cancer Treatment: New Phase 2 Data Shows 64% Survival Rate at 6 Months - Stock Titan
AIM ImmunoTech (NYSE:AIM) Stock Price Down 4.5% – Here’s What Happened - Defense World
AIM ImmunoTech granted U.S. patent for Ampligen - MSN
0.11%
1.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):